Metformin treatment of antipsychotic-induced dyslipidemia: analysis of two randomized, placebo-controlled trials.
10.11817/j.issn.1672-7347.2019.180379
- Author:
Ye YANG
1
;
Xiaoyi WANG
1
;
Dongyu KANG
1
;
Yujun LONG
1
;
Jianjun OU
1
;
Wenbin GUO
1
;
Jingping ZHAO
1
;
Renrong WU
1
Author Information
1. Mental Health Institute, Second Xiangya Hospital, Central South University, Changsha 410011, China.
- Publication Type:Journal Article
- MeSH:
Antipsychotic Agents;
adverse effects;
Blood Glucose;
Diabetes Mellitus, Type 2;
Double-Blind Method;
Dyslipidemias;
chemically induced;
drug therapy;
Humans;
Hypoglycemic Agents;
Metformin;
therapeutic use
- From:
Journal of Central South University(Medical Sciences)
2019;44(10):1128-1136
- CountryChina
- Language:Chinese
-
Abstract:
To examine the efficacy and safety for metformin in treating antipsychotic-induced dyslipidemia.
Methods: Two randomized placebo-controlled trials were included in the analysis. A total of 201 schizophrenia patients with dyslipidemia after treatment with an antipsychotic were collected, and the patients were divided into two groups: a 1 000 mg/d metformin group (n=103) and a placebo group (n=98). The clinical symptoms and metabolic indicators such as body weight, blood glucose, and blood lipids were assessed at baseline, the 12th week and the 24th week after treatment respectively.
Results: After metformin treatment, the mean difference in the low-density lipoprotein cholesterol (LDL-C) value between the metformin group and the placebo group was from 0.16 mmol/L at baseline to -0.86 mmol/L at the end of the 24th week, which was decreased by 1.02 mmol/L
(P<0.01). At the 24th week, the LDL-C was more than 3.37 mmol/L in 25.3% patients in the metformin group, which was significantly lower than that in the placebo group (64.8%) (P<0.01). Compared with the placebo group, there were significant changes in the weight, body mass index (BMI), insulin, insulin resistance index, total cholesterol and triglyceride, and high-density lipoprotein cholesterol (HDL-C) in the metformin group (all P<0.05). The treatment effects on weight and insulin resistance appeared at the 12th week and further improved at the 24th week, but the effects on improving dyslipidemia only significantly occurred at the end of the 24th week.
Conclusion: The metformin treatment is effective in improving antipsychotic-induced dyslipidemia and insulin resistance, and the effect to reduce the antipsychotic-induced insulin resistance appears earlier than the effect to improve dyslipidemia.
